EC |
HUVECs |
IL-11 ↑ |
CMV stimulation |
|
(17) |
HUVECs |
|
CTL damage |
Resist HUVECs damage |
(25) |
HUVEC, HPMEC |
|
H2O2 damage |
Decrease cell death |
(26) |
Human RA ST endothelial cells |
IL-11 ↑ |
RA |
Induce angiogenesis |
(38) |
Human retinal microvessels Endothelial cells |
IL-11, IL-11RA ↑ |
PDR patients |
Induce angiogenesis |
(64) |
Mouse endothelial cells |
|
Human skin allograft model |
Protect endothelial cells by survivin |
(19) |
VSMCs |
Human aorta VSMCs |
IL-11 ↑ |
TGF-β stimulation |
|
(31) |
Mouse aorta VSMCs |
IL-11 ↑ |
Aortic coarctation model Ang II stimulation |
Induce VSMCs phenotypic transformation |
(32) |
Human coronary arteries VSMCs |
IL-11 ↓ |
Early coronary atherosclerosis patients |
|
(18) |
PASMCs |
IL-11, IL-11RA ↑ |
IPF and PH patients |
Induce PASMCs phenotypic transformation |
(51) |
Mouse aorta VSMCs |
IL-11 ↑ |
Marfan syndrome model |
IL-11 inhibition reduces aortic inflammation, fibrosis |
(13) |
Mouse carotid artery VSMCs |
|
Carotid artery injury + high fat diet model |
IL-11 inhibition reduces VSMCs phenotypic transformation and vascular fibrosis |
(20) |
Fibroblast |
Human lung Fibroblasts |
IL-11 ↑ |
IPF patients |
Induce fibroblasts transform into myofibroblasts |
(51) |
Mouse thoracic aorta fibroblasts |
IL-11 ↑ |
AngII hypertension model |
IL-11 inhibition reduces vascular fibrosis |
(21) |
Serum |
Human venous blood |
IL-11 ↓ |
CAD patients |
|
(42) |
Human arterial blood |
IL-11 ↑ |
CAD patients |
|
(41) |
Human serum |
IL-11 ↑ |
Spontaneous intracerebral hemorrhage |
Associate with hydrocephalus and mortality after intracerebral hemorrhage |
(55) |
Human serum |
IL-11 ↑ |
HICH |
Associate with disease severity and prognosis |
(56) |
Human serum |
IL-11 ↑ |
AD patients |
|
(60) |
Mouse serum |
IL-11 ↑ |
PE |
|
(49) |